Bristol Myers Squibb reported that Reblozyl (luspatercept) failed to meet the primary endpoint in a Phase III INDEPENDENCE trial for treating anemia in myelofibrosis patients, specifically failing to achieve statistically significant red blood cell transfusion independence. Despite this, the company cited clinically meaningful improvements in secondary endpoints and plans to discuss potential regulatory submissions with FDA and EMA for this indication. Analysts acknowledged the lack of approved treatments in this space, accentuating an unmet medical need alongside promising albeit inconclusive trial data.